XORTX Announces Positive Phase 2 Results in Type 2 Diabetic Nephropathy (T2DN)

    NEXT STORY
    PM360 Magazine Announces Winners of 2019 Trailblazer Awards
    PREV STORY
    Blood Advances Publishes Cellworks Prospective Genomic Biosimulation Study that Predicts Cancer Therapy Response with 90% Accuracy
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Phase 2 data of selatogrel, Idorsia’s highly-selective P2Y12 receptor antagonist, presented at ESC 2019

    author_avatar
    NASDAQ Market News

    Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer

    author_avatar
    NASDAQ Market News

    BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Hepatocellular Carcinoma

    CAMBRIDGE, Mass. and BEIJING, China, Jan. 02, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), ...

    author_avatar
    NASDAQ Market News